Nutra Pharma Announces Jordan Distributor for Their Nyloxin Pain Relievers

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has selected MedicinesConsult to serve as the exclusive distributor in Jordan for its Nyloxin-branded pain relievers.

"Nutra Pharma continues to increase awareness internationally and while we are establishing the framework for international distribution of our pain relievers,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "MedicinesConsult has already begun the registration process for our Nyloxin products in Jordan and will begin an aggressive marketing campaign throughout the Middle East once they have regulatory clearance,” he added.

MedicinesConsult is known for their highly experienced management and consultant marketers who have broad experience in the medical field, including: prescription and OTC drugs, biotech products, medical equipment and medical devices. MedicinesConsult works directly with the Jordanian Ministry of Health, Military and Governmental Hospitals, private hospitals, and other health institutions in Jordan with the mission to provide the Jordanian market, as well as the Middle East and North Africa markets, with high quality medical products for human use.

Recently, the Jordan Food and Drug Administration (JFDA) have warned the public against extensive use of painkillers containing paracetamol (acetaminophen) because of the associated risk of liver damage. Additionally, it was reported in the November 1, 2010 issue of The Jordan Times that although Jordanians consume the most painkillers in the region, more needs to be done to improve access to necessary drugs. According to the Jordanian Pain Society (JPS), Jordan was ranked 59th internationally and first regionally in the consumption of painkillers in 2008. According to JPS Secretary General Ahmad Khatib, more efforts are needed to improve access to painkillers in Jordan to reach international averages. General Khatib noted that the sub-average rates are due to the belief of health institutions and physicians that the use of painkillers leads to addiction and their related refusal to prescribe the drugs to their patients -- hence the necessity for a non-addictive alternative.

Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

Previously, Nutra Pharma announced agreements with distributors in Mexico, Colombia, Venezuela and Lebanon. The drug registration process for both Cobroxin® and Nyloxin™ are currently being pursued in more than 20 countries.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Jordanian distribution of Nyloxin™ through MedicinesConsult should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. Additionally, this distribution agreement does not ensure that the Company will have material sales in Jordan. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.